A patient was administered a muscle relaxant and subsequently developed erythema, facial flushing, and hypotension. Which drug is most likely responsible for these symptoms?

Explanation

## Correct Answer: A. Atracurium Atracurium is a benzylisoquinolinium compound that causes **histamine release** from mast cells and basophils—a unique pharmacological property among neuromuscular blocking agents (NMBAs). This histamine release is the discriminating feature that explains the clinical triad: erythema (cutaneous vasodilation), facial flushing (generalized vasodilation), and hypotension (systemic vasodilation and potential direct myocardial depression). The reaction is dose-dependent and more pronounced with rapid IV administration. Atracurium undergoes Hofmann elimination (temperature and pH-dependent degradation) and ester hydrolysis, making it suitable for patients with hepatic or renal impairment, but this advantage comes at the cost of histamine-mediated side effects. In Indian anaesthetic practice, atracurium remains commonly used for intermediate-duration paralysis, but clinicians must anticipate and manage histamine release—particularly in rapid-sequence intubation scenarios. Premedication with H1 and H2 blockers (e.g., promethazine + ranitidine) or slow administration can mitigate these effects. The constellation of erythema, flushing, and hypotension is pathognomonic for atracurium among the benzylisoquinolinium agents. ## Why the other options are wrong **B. Rocuronium** — Rocuronium is a steroidal NMBA with **minimal histamine release** and does not cause the erythema–flushing–hypotension triad. It undergoes hepatic metabolism and is excreted renally. While rocuronium can rarely cause anaphylaxis (via IgE-mediated mechanisms unrelated to histamine), it does not produce the acute vasodilatory symptoms described. This is a common trap: students may confuse rocuronium's anaphylactic potential with atracurium's predictable histamine release. **C. Vecuronium** — Vecuronium is a steroidal NMBA with **no significant histamine release**. Like rocuronium, it undergoes hepatic metabolism and biliary excretion. Vecuronium is often chosen specifically to avoid histamine-related side effects in patients at risk for anaphylaxis or hemodynamic instability. The absence of the erythema–flushing–hypotension triad makes vecuronium an unsuitable answer despite its clinical utility. **D. Cisatracurium** — Cisatracurium is the active stereoisomer of atracurium and undergoes **Hofmann elimination without significant histamine release**. Although structurally related to atracurium, cisatracurium was specifically engineered to eliminate histamine-releasing properties while retaining the pharmacokinetic advantage of temperature/pH-dependent degradation. This makes cisatracurium the preferred benzylisoquinolinium agent in modern practice, particularly in India where it is increasingly available. ## High-Yield Facts - **Atracurium** is the only commonly used NMBA that causes **histamine release** from mast cells, producing erythema, flushing, and hypotension. - **Histamine release from atracurium** is dose-dependent and exacerbated by rapid IV administration; slow infusion or premedication with H1/H2 blockers reduces incidence. - **Cisatracurium** (active stereoisomer of atracurium) undergoes Hofmann elimination **without histamine release**, making it the preferred benzylisoquinolinium agent. - **Steroidal NMBAs** (rocuronium, vecuronium) undergo hepatic metabolism and have **no histamine release**, but may rarely cause anaphylaxis via IgE mechanisms. - **Atracurium metabolism**: Hofmann elimination (temperature/pH-dependent) + ester hydrolysis; independent of liver/kidney function, ideal for hepatorenal failure. ## Mnemonics **HIST-A (Histamine from Atracurium)** **H**istamine release → **I**ncreased vasodilation → **S**kin erythema → **T**achycardia/hypotension → **A**tracurium. Use this when you see flushing + hypotension + NMBA. **Benzyl = Histamine; Steroid = Safe** **Benzylisoquinolinium** (atracurium, cisatracurium, mivacurium) → histamine risk. **Steroidal** (rocuronium, vecuronium, pancuronium) → no histamine. Quick discriminator for NMBA side effects. ## NBE Trap NBE pairs the non-specific symptom triad (erythema, flushing, hypotension) with NMBAs to test whether students know that **only atracurium causes histamine release**. The trap is that rocuronium and vecuronium can cause anaphylaxis, leading students to confuse anaphylaxis (rare, IgE-mediated) with atracurium's predictable, dose-dependent histamine release (common, mast-cell-mediated). ## Clinical Pearl In Indian operating theatres, atracurium remains a first-line NMBA for intermediate paralysis due to cost and availability, but anaesthetists routinely premedicate with IV ranitidine (50 mg) + promethazine (0.5 mg/kg) and administer atracurium slowly over 30–45 seconds to prevent the histamine-mediated triad. Cisatracurium, though more expensive, is increasingly preferred in high-risk patients (severe asthma, anaphylaxis history) because it eliminates this complication entirely. _Reference: KD Tripathi Ch. 12 (Neuromuscular Blocking Agents); Harrison Ch. 476 (Anesthesia)_